PCVX
Vaxcyte, Inc.43.67
-0.67-1.51%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
5.72BP/E (TTM)
-Basic EPS (TTM)
-4.85Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
Vaxcyte signs manufacturing pact
Vaxcyte inked a 15-year Master Services Agreement with Patheon's Thermo Fisher unit on September 24, 2025, to manufacture drug product at a North Carolina facility. The deal locks in minimum orders at set prices, with tech transfer fees and capital reimbursements, but termination for convenience triggers mid-eight-figure payouts. This secures long-term supply yet ties Vaxcyte to hefty exit costs.
8-K
Vaxcyte Q2 results and VAX-31 update
Vaxcyte reported Q2 2025 net loss of $166.6 million, up from $128.7 million last year, driven by $194.2 million in R&D expenses for PCV programs. Cash reserves stand at $2.8 billion, funding operations to mid-2028 after streamlining early-stage pipeline. Adult VAX-31 Phase 3 non-inferiority study starts Q4 2025, with topline data in 2026. Pipeline focus sharpens resources.
10-Q
Q2 FY2025 results
Vaxcyte's Q2 FY2025 results showed operating expenses climbing 47.9% y/y to $226.2M, driven by ramped-up R&D on PCV programs, while net loss widened 29.4% y/y to $166.6M, cushioned by $59.6M in other income from interest and forex gains. No revenue yet, but cash and investments stood at $2.8B, down from $3.1B year-end, with operating cash burn at $287.4M YTD—free cash flow not disclosed in the 10-Q. EPS dipped to $(1.22) from $(1.10) y/y, reconciling to 136M diluted shares. Liquidity remains solid, bolstered by prior offerings, yet manufacturing reliance on Lonza carries supply risks. Competition from Pfizer and Merck looms large.
BVAXD
BioVaxys Technology Corp.
0.15-0.03
GOVX
GeoVax Labs, Inc.
0.29-0.05
HLVX
HilleVax, Inc.
2.09+0.00
INO
Inovio Pharmaceuticals, Inc.
2.32+0.06
NVAX
Novavax, Inc.
6.54-0.04
PDSB
PDS Biotechnology Corporation
0.90-0.02
STRO
Sutro Biopharma, Inc.
9.81-0.12
VALN
Valneva SE
8.34-0.23
VINC
Vincerx Pharma, Inc.
0.01+0.00
VXRT
Vaxart, Inc.
0.37+0.01